Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Consumers overall high satisfaction with these medications for weight loss has been tempered primarily by concerns about side effects, weight gain if discontinued, and cost, said Kathy Risch, SVP, Shopper Insights and Thought Leadership, Acosta Group
The results were remarkable
Emergencies: call 911 Online care is not for emergencies
Rob Davis, Merck CEO (Jeenah Moon/Bloomberg via Getty Images) December 18, 2024 10:18 AM EST Deals China Pharma Mercks long-awaited obesity move is an oral GLP-1 from China Kyle LaHucik Biotech Correspondent Merck is finally making a move in obesity by licensing an oral GLP-1 candidate, though its happening years after some of its big pharma peers
Liraglutide Liraglutide is a long-acting GLP-1 RA approved both domestically and internationally for treating type 2 diabetes and for long-term weight management in obese or overweight patients aged 12 years and older
Concerns over more severe adverse effects, including pancreatitis and possible thyroid tumors, may further deter both patients and healthcare providers from utilizing these medications
